169 related articles for article (PubMed ID: 33822606)
21. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
[TBL] [Abstract][Full Text] [Related]
22. Development of targeted near-infrared imaging agents for prostate cancer.
Wang X; Huang SS; Heston WD; Guo H; Wang BC; Basilion JP
Mol Cancer Ther; 2014 Nov; 13(11):2595-606. PubMed ID: 25239933
[TBL] [Abstract][Full Text] [Related]
23. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.
Derks YHW; Rijpkema M; Amatdjais-Groenen HIV; Kip A; Franssen GM; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Lütje S; Heskamp S
Theranostics; 2021; 11(4):1527-1541. PubMed ID: 33408764
[TBL] [Abstract][Full Text] [Related]
24. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Böhnke N; Indrevoll B; Hammer S; Papple A; Kristian A; Briem H; Celik A; Mumberg D; Cuthbertson A; Zitzmann-Kolbe S
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):669-680. PubMed ID: 37882848
[TBL] [Abstract][Full Text] [Related]
25. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
[TBL] [Abstract][Full Text] [Related]
26. Fluorescence Detection of Prostate Cancer by an Activatable Fluorescence Probe for PSMA Carboxypeptidase Activity.
Kawatani M; Yamamoto K; Yamada D; Kamiya M; Miyakawa J; Miyama Y; Kojima R; Morikawa T; Kume H; Urano Y
J Am Chem Soc; 2019 Jul; 141(26):10409-10416. PubMed ID: 31244179
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and preliminary evaluation of
Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
29. Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
Leamon CP; Reddy JA; Bloomfield A; Dorton R; Nelson M; Vetzel M; Kleindl P; Hahn S; Wang K; Vlahov IR
Bioconjug Chem; 2019 Jun; 30(6):1805-1813. PubMed ID: 31075200
[TBL] [Abstract][Full Text] [Related]
30. Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging.
Harada N; Kimura H; Ono M; Saji H
J Med Chem; 2013 Oct; 56(20):7890-901. PubMed ID: 24063417
[TBL] [Abstract][Full Text] [Related]
31. PSMA-targeted low-molecular double conjugates for diagnostics and therapy.
Petrov SA; Zyk NY; Machulkin AE; Beloglazkina EK; Majouga AG
Eur J Med Chem; 2021 Dec; 225():113752. PubMed ID: 34464875
[TBL] [Abstract][Full Text] [Related]
32. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
[TBL] [Abstract][Full Text] [Related]
33. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
[TBL] [Abstract][Full Text] [Related]
34. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
[TBL] [Abstract][Full Text] [Related]
35. Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.
Bakht MK; Hayward JJ; Shahbazi-Raz F; Skubal M; Tamura R; Stringer KF; Meister D; Venkadakrishnan VB; Xue H; Pillon A; Stover M; Tronchin A; Fifield BA; Mader L; Ku SY; Cheon GJ; Kang KW; Wang Y; Dong X; Beltran H; Grimm J; Porter LA; Trant JF
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35064078
[TBL] [Abstract][Full Text] [Related]
36. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
38. Development of small molecule-drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells.
Obara T; Kawano N; Tatsumi K; Katsuyama A; Nakajima K; Ogawa M; Ichikawa S
Bioorg Med Chem; 2024 Jun; 108():117773. PubMed ID: 38850999
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of a novel urea-based
Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
[TBL] [Abstract][Full Text] [Related]
40. (
Duan X; Liu F; Kwon H; Byun Y; Minn I; Cai X; Zhang J; Pomper MG; Yang Z; Xi Z; Yang X
J Med Chem; 2020 Apr; 63(7):3563-3576. PubMed ID: 32207938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
